RxDoctor Payments DataLook up a doctor →

Kevin Winders, MD

Child & Adolescent Psychiatry · Savannah, GANPI 1275577520

Payments from drug & device makers

$225,384in general payments, 2019–2025

Across 750 payments — averaging $300.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$185K
  • Supernus Pharmaceuticals, Inc.$25K
  • Takeda Pharmaceuticals U.S.A., Inc.$10K
  • Corium, LLC$557
  • Teva Pharmaceuticals USA, Inc.$468
  • Ironshore Pharmaceuticals Inc.$449
  • plus $4K from 23 others

What the payments were for

  • Speaking & faculty fees$208,91593%
  • Travel & lodging$6,5703%
  • Food & beverage$9,8344%
  • Education$650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$225,384 in reported general payments places this provider in the 95th percentile of 91 child & adolescent psychiatry providers in Georgia.

See all child & adolescent psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$72,176
Medicare patients
126
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide47$32,197
VyvanseLisdexamfetamine Dimesylate16$6,911
Adderall XrDextroamphetamine/Amphetamine11$6,632
Desvenlafaxine Succinate ErDesvenlafaxine Succinate36$5,951
Lisdexamfetamine Dimesylate14$3,565
Bupropion XlBupropion Hcl92$3,072
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine52$2,536
Vilazodone Hcl11$1,626
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine62$1,530
Escitalopram Oxalate103$1,152
Duloxetine Hcl38$953
Carbamazepine ErCarbamazepine12$860
Trazodone Hcl57$690
Buspirone Hcl52$618
Quetiapine Fumarate55$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$9,878$39,10763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 91 child & adolescent psychiatry providers in Georgia.

Other child & adolescent psychiatry in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →